nlrp 3

NLRP3/AIM2-IN-3 is a unique molecule that inhibits NLRP3 and AIM2 inflammasome activation in a species-specific manner. It has an IC50 value for cell lysis of 0.077 ± 0.008 μ M. NLRP3/AIM2-IN-3 is a potent inhibitor of NLRP3 and AIM2 inflammasome-dependent cell lysis with an IC50 value for cell lysis of 0.077 ± 0.008 μ M. NLRP3/AIM2-IN-3 inhibits LPS/nigericin NLRP3/AIM2-IN-3 inhibits LPS/nigericin-stimulated cell lysis in THP-1 macrophages with an IC50 value of 0.077 ± 0.008 μM. NLRP3/AIM2-IN-3 interferes with the interaction of NLRP3 or AIM2 with the bridging protein ASC, inhibiting oligomerization of ASC.

NLRP3-IN-13 is a selective NLRP3 inhibitor that inhibits NLRP3-associated inflammation.NLRP3-IN-13 can be used in the study of neurological disorders and inflammation.

NLRP3-IN-9 (INF-4E) is an inhibitor of NLRP3 ATPase and caspase-1. NLRP3-IN-9 acts by irreversibly trapping thiol nucleophiles, which prevents both ATP- and nigericin-triggered pyroptosis of human THP-1 cells in a time- and concentration-dependent manner.

NLRP3/AIM2-IN-2 is a novel potent inhibitor with different species-specific effects on NLRP3 and AIM2 inflammasome dependent pyroptosis with IC50 of 0.2392 ± 0.0233 μ M.

NLRP3-IN-11 is an NLRP3 protein inhibitor with potential anti-inflammatory activity.NLRP3-IN-11 can be used in the study of atherosclerosis and parkinsonism.

NLRP3-IN-10 (ZVN26391) is a potent NLRP3 inhibitor. NLRP3-IN-10 inhibits IL-1β release with an IC50 value of 251.1 nM. NLRP3-IN-10 attenuates ASC speck formation, leading to suppress activation of NLRP3 inflammasome.

NLRP3 agonist 1 is an orally active and highly potent NLRP3 agonist that activates the enzyme Caspase-1, which may promote the maturation of pro-inflammatory cytokines.

NLRP3 modulators 1 (WO2017184746A1, compound 107) is a potent modulator of NLRP3, capable of agonizing or partially agonizing the activity of NLRP3. This compound proves valuable in investigating conditions, diseases, or disorders where a reduction in LRP3 activity plays a role in the pathology.

NLRP3-IN-53 (compound 1) is an NLRP3 inhibitor with an IC50 of 3.4nM.

NLRP3-IN-56 (compound 062) is an inhibitor of NLRP3. It effectively suppresses the secretion of IL-1β in THP-1 cells, demonstrating an IC50 of 9.7 nM. NLRP3-IN-56 is useful for research into NLRP3-mediated symptoms and/or diseases.

NLRP3-IN-58 (Compound DS15) acts as an inhibitor of NLRP3 inflammasome activation, with an IC50 value of 3.85 μM, and is capable of inhibiting 33% of IL-1β release at a concentration of 10 μM.

NLRP3-IN-66 (example 257) is a potent inhibitor of the NLRP3 inflammasome.

NLRP3-IN-61 (Compound 1) is an inhibitor of NLRP3. It suppresses pyroptosis in THP-1 cells with an IC50 of 12.6 nM and inhibits IL-β release with an IC50 of 25.3 nM.

NLRP3-IN-65 (compound 41) is a potent inhibitor of NLRP3.

NLRP3-IN-63 (Compound 7) is an inhibitor of NLRP3, effectively suppressing NLRP3 activation with an EC50 of 13 nM.

NLRP3-IN-67 (compound 42) is an effective inhibitor of NLRP3.

NLRP3-IN-62 (Compound 1) is an inhibitor of NLRP3. It effectively inhibits pyroptosis in THP-1 cells with an IC50 of 0.7 nM and suppresses IL-β release with an IC50 of 108.5 nM.

NLRP3-IN-64 (Compound 2) is an inhibitor of NLRP3, effectively suppressing its activation with an EC50 of 5 nM.

NLRP3 IN 70 (compound 15) exhibited the potent NLRP3 inhibitory activity, effectively suppressing IL-1β secretion in THP-1 (IC50 = 23 nM).

NLRP3 IN 7n (compound 7n) specifically inhibited NLRP3 activation at nanomolar concentrations without affecting the activation of the NLRC4 and AIM2 inflammasomes.

NLRP3-IN-71 (Compound 19) is an orally active and selective NLRP3 inhibitor that can cross the blood-brain barrier and inhibit IL-1 β secretion. Can be used for research on neurodegenerative diseases.

NLRP3-IN-60 (Compound 39) is an orally bioavailable inhibitor of NLRP3. It effectively suppresses pyroptosis in THP-1 cells with an IC50 of 13 nM and inhibits IL-1β release in human whole blood, exhibiting an IC50 of 225 nM.

NLRP3-IN-68 (Compound 2d) is a derivative of 1,3,4-oxadiazole. It exhibits significant anti-inflammatory and antioxidant properties, effectively inhibiting the secretion of inflammatory cytokines, the expression of iNOS, and the activation of the NLRP3 inflammasome. NLRP3-IN-68 is applicable in the research of anti-inflammatory drugs.

NLRP3-IN-69 (Compound 23) inhibits the activation of NF-κBp65 and the formation of the NLRP3 inflammasome. It suppresses the overexpression of IL-1β, iNOS, and COX-2 induced by LPS, and inhibits the production of NO (IC50=5.66 μM), thereby demonstrating anti-inflammatory activity.